Founder/CEO
Miriam O’Reilly
Miriam O’Reilly, Founder of Haim Pharma Group, is a visionary leader driven by a deep passion for advancing innovative treatments for neurodegenerative diseases. With a Bachelor’s degree in Mechanical Engineering and a Master’s in Industrial Engineering Management, Miriam brings 20 years of proven expertise in establishing and leading operations and managing complex, high-stakes projects.
Her track record includes successfully navigating the intricate process of bringing EU GMP-certified medical cannabis to the UK market, demonstrating her ability to overcome regulatory, operational, and market-entry challenges with precision and determination. Her leadership reflects a combination of technical expertise and strategic insight, setting a strong foundation for Haim Pharma’s ambitious mission.
Miriam and her team are united in their belief that they can shape the future of neurodegenerative disease treatment. With their collective expertise and unwavering dedication, they are committed to creating innovative therapies that will transform patient care and improve lives worldwide.
Advisors
Haim Pharma Group pioneers the development and commercialization of psilocin-based treatments for neurodegenerative diseases. Guided by a highly experienced team and advisory board, the company employs a strategic approach to drug development, ensuring excellence in regulatory navigation, clinical execution, and market entry. This collective expertise positions Haim Pharma to successfully advance innovative solutions tailored to the needs of patients worldwide.
Esther Howard
Esther Howard has a distinguished track record in leading oncology drug development, successfully transitioning multiple therapies from the laboratory to commercial markets. Her expertise spans global research initiatives, regulatory compliance, financial oversight, operational management, and digital health innovation. Her leadership ensures that Haim Pharma’s projects are scientifically sound and commercially viable.
Dr. Ayelet Karminitz
Dr. Ayelet Kaminitz, lab manager at Tel Aviv University, completed her Ph.D. at the same institution and pursued postdoctoral research at the Immunology Department of the Weizmann Institute. Her research expertise focuses on the peripheral tolerance mechanisms in autoimmune diseases such as diabetes and multiple sclerosis, bringing critical insights into the immune aspects of neurodegenerative conditions.
Robin De Bruijn
Robin De Bruijn is a seasoned expert in drug delivery systems and a co-founder of several successful companies. With over a decade of experience, he has worked across pharma, biotech, and medtech sectors, leveraging his Master’s degrees in Process Engineering and Business Innovation to drive cutting-edge solutions. Robin excels in bridging technical expertise and strategic insight to develop and commercialize groundbreaking therapies.
Rachel Collins
Rachel Collins combines her expertise in project management, programming, and business development with a strong entrepreneurial spirit. With extensive experience in marketing and fundraising, she plays a vital role in driving Haim Pharma’s strategic growth and operational success. Her ability to navigate complex challenges and deliver innovative solutions makes her an essential contributor to the company’s mission.
Dr. Keren Farin
Dr. Karin Farin holds a Ph.D. in Neurobiology and is a certified Patent Attorney. With extensive experience in developing and managing intellectual property strategies for biomedical and biotechnology companies, she ensures that Haim Pharma’s innovations are strategically protected. Her dual expertise in neurobiology and IP law uniquely positions her to bridge scientific discovery and commercial success.
Collaborators
Collaboration is at the foundation of HPG. It provides rapid access to industry experts and cutting-edge facilities. This approach enhances flexibility and accelerates project timelines. It provides immediate access to essential infrastructure and experts. This allows us to leverage world-class resources.
Since our foundation in 2022, we have fostered strong collaborations with leading researchers in the field of neurodegenerative diseases. These strategic partnerships will enable us to execute comprehensive pharmaceutical product development, focusing on patient-specific treatments and scientifically-backed dosing strategies.
